This Article Abstract Full Text Full Text (PDF) Correction (v47,p1739) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vyas, A. K. Search for Related Content PubMed PubMed Citation Articles by Vyas, A. K.

Reduction in Ventricular Tachyarrhythmias With Statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II

Anant K. Vyas, MD, MPH^_*,_*, Hongsheng Guo, MD, Arthur J. Moss, MD^_*, Brian Olshansky, MD, Scott A. McNitt, MS^_*, W. Jackson Hall, PhD, Wojciech Zareba, MD, PhD^_*, Jonathan S. Steinberg, MD^||, Avi Fischer, MD^||, Jeremy Ruskin, MD^¶, Mark L. Andrews, BBA^_* for the MADIT-II Research Group

^_* Heart Research Follow-up Program of the Cardiology Unit of the Department of Medicine, University of Rochester Medical Center, Rochester, New York
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York
Cardiac Electrophysiology Division, Park Nicollet Clinic, St. Louis Park, Minnesota
University of Iowa Hospitals, Iowa City, Iowa
^|| Cardiology Division of the Department of Medicine, St. Luke’s Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York, New York
^¶ Cardiology Division of the Department of Medicine, Massachusetts General Hospital and Harvard University, Boston, Massachusetts.

View larger version (15K): [in a new window]   Figure 1 Frequency distribution of the percentage of days during follow-up on which the implantable cardioverter-defibrillator treated patients (n = 654) received statin drugs.

View larger version (22K): [in a new window]   Figure 2 (A) Cumulative probability of appropriate implantable cardioverter-defibrillator (ICD) therapy for cardiac death or ventricular tachycardia/ventricular fibrillation (VT/VF) by percentage of days that statin therapy was used (90%, 11% to 89%, and 10%) during follow-up. Numbers below each graph are the number of patients at risk in the time period; the p value assesses differences among the three curves. (B) Cumulative probability of appropriate ICD therapy for VT/VF by percentage of days that statin therapy was used (90%, 11% to 89%, and 10%) during follow-up. Numbers below each graph are the number of patients at risk in the time period; the p value assesses differences among the three curves.

View larger version (20K): [in a new window]   Figure 3 (A) Cumulative probability of death classified as sudden cardiac, by percentage of days that statin therapy was used (90%, 11% to 89%, and 10%) during follow-up. Numbers below each graph are the number of patients at risk in the time period; the p value assesses differences among the three curves. (B) Cumulative probability of death classified as non-sudden cardiac, by percentage of days that statin therapy was used (90%, 11% to 89%, and 10%) during follow-up. Numbers below each graph are the number of patients at risk in the time period; the p value assesses differences among the three curves.